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Abstract
Background: Children with Acute Lymphoblastic Leukemia (ALL) diagnosed with resistant phenotypes and those
who relapse have a dismal prognosis for cure. In search for novel treatment strategies, we identified the AMP
activated protein kinase (AMPK) as a potential drug target based on its effects on cell growth and survival. We
have shown previously that AICAR-induced AMPK activation also induced a compensatory survival mechanism via
PI3K/Akt signaling.
Results: In the present study, we further investigated the downstream signaling induced by AMPK activation in
ALL cells. We found that AICAR-induced AMPK activation resulted in up-regulation of P-Akt (Ser473 and Thr308)
and decrease of P-mTOR (Ser2448) expression and downstream signaling. We determined that activation of P-Akt
(Thr308) was mediated by AMPK-induced IGF-1R activation via phosphorylation of the insulin receptor substrate-1
(IRS-1) at Ser794. Inhibition of IGF-1R signaling using the tyrosine kinase inhibitor HNMPA(AM)3 resulted in
significant decrease in P-IRS-1 (Ser794) and P-Akt (Thr308). Co-treatment of AICAR plus HNMPA(AM)3 prevented
AMPK-induced up-regulation of P-Akt (Thr308) but did not alter the activation of P-Akt (Ser473). Inhibition of AMPK
using compound-C resulted in decreased P-Akt expression at both residues, suggesting a central role for AMPK in
Akt activation. In addition, inhibition of IGF-1R signaling in ALL cells resulted in cell growth arrest and apoptosis.
Additional Western blots revealed that P-IGF-1R (Tyr1131) and P-IRS-1 (Ser794) levels were higher in NALM6 (Bp-
ALL) than CEM (T-ALL), and found differences in IGF-1R signaling within Bp-ALL cell line models NALM6, REH (TEL-
AML1, [t(12;21)]), and SupB15 (BCR-ABL, [t(9;22)]). In these models, higher sensitivity to IGF-1R inhibitors correlated
with increased levels of IGF-1R expression. Combined therapy simultaneously targeting IGF-1R, AMPK, Akt, and
mTOR pathways resulted in synergistic growth inhibition and cell death.
Conclusions: Our study demonstrates that AMPK activates Akt through IGF-1R dependent and independent
mechanisms. Co-targeting IGF-1R and related downstream metabolic and oncogenic signaling pathways represent
a potential strategy for future translation into novel ALL therapies.
Background
Acute Lymphoblastic Leukemia (ALL) is the most com-
mon hematological malignancy affecting children and
adolescents, and remains the leading cause of cancer-
related mortality in this age group [1]. ALL is a hetero-
geneous disease with distinct phenotypes segregated by
the presence of non-random translocations and genomic
deletions and amplifications [2]. Despite significant
progress in the treatment of ALL, a large number of
children continue to relapse and for them, outcome
remains poor. In addition, adults are generally diagnosed
with resistant phenotypes of ALL and continue to
respond poorly to existing treatment regimens. There-
fore, novel therapies need to be developed. Recently, our
laboratory identified AMP activated protein kinase
(AMPK) as a potential target for ALL therapy due to its
effects on cell growth and its signaling crosstalk with
critical metabolic and oncogenic pathways [3]. Treat-
ment with the AMPK activator 5-aminoimidazole-4-car-
boxamide-1-b-D-ribofuranoside (AICAR) induced
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apoptotic cell death in ALL cells mediated by AMPK,
mTOR, P27, P53, and p38-MAPK [3]. In addition,
AICAR significantly increased P-Akt (Ser473) following
AMPK activation and mTOR down-regulation, which
was viewed as a compensatory survival mechanism. Akt
(protein kinase B) is involved in critical survival path-
ways, and inhibits apoptosis via phosphorylation of the
pro-apoptotic protein BAD at Ser136, which prevents its
inhibitory association with the anti-apoptotic Bcl-2 pro-
tein [4-6]. Akt is activated by phosphorylation of two
key residues: Thr308 within the T-loop of its catalytic
domain, and Ser473 located in the hydrophobic region
of its C-terminal domain [7,8]. Phosphorylation of both
residues is essential for maximal activity [8] and was
found to be regulated by independent mechanisms [9].
Phosphorylation of Akt at Ser473 involves rictor, a
member of the TORC2 complex known to modulate the
activity of mTOR [7,10-12], while phosphorylation of
Thr308 is mediated by PDK1 and PIP3 following phos-
phorylation of PIP2 by PI3K [13,14]. The latter mechan-
ism is responsible for the described feedback loop
inhibition of Akt phosphorylation mediated by mTOR-
dependent phosphorylation of IRS-1 at Ser312, the
immediate downstream effector protein of the insulin-
like growth factor-1 receptor (IGF-1R) [15,16]. Phos-
phorylation of IRS-1 (Ser312) by P-mTOR promotes
conformational changes and subsequent detachment
from the receptor and degradation [17], and inhibits
potentiation of Akt by IGF-1R/IRS-1 signaling [18].
Conversely, inhibition of mTOR results in IRS-1 activa-
tion and increased phosphorylation of Akt at Thr308
[19].
IGF-1R is one of four transmembrane receptors (IGF-
1R, IGF-IIR, IR, and hybrids receptors of IGF and IR)
that compose the IGF-1R signaling system in addition
to the three circulating ligands (IGF-I, IGF-II, and insu-
lin) and multiple regulatory IGF-binding proteins
(IGFBP-1 to -6) [20-23]. IGF-1R is ubiquitously
expressed in human cancer cells compared to normal
tissues [24]. Elevated plasma concentrations of IGF-1,
IGFBP-2, and IGFBP-3 have been linked to more
aggressive phenotypes in breast, colon, prostate, lung
cancer, and ALL [25,26]. IGF-1R exerts its action
through activation of downstream signaling cascades
that regulate metabolic and oncogenic pathways impor-
tant for cellular growth [27]. IGF-1R signaling has been
linked to the regulation of normal and malignant hema-
topoietic cells. Significant differences in the expression
of the IGF-1 system components IGF-II, IGFBP-2,
IGFBP-4 and IGFBP-5 have been found between B-line-
age and T-lineage ALL [28-30]. Taken together, this
suggests that activation of IGF-1R signaling and its
downstream pathways may confer ALL cells a survival
advantage by influencing growth and metabolic
adaptations aimed at supporting accelerated growth.
Therefore, to delineate the mechanism responsible for
ALL cell survival regulated by AMPK and IGF-1R and
to understand the role of IGF-1R in this process, we
investigated the relationship between AMPK and the
cell proliferation and survival pathways downstream of
IGF-1R/IRS-1. As a result, we uncovered potential com-
bination therapies that simultaneously target key factors
within these signaling cascades.
Results
AICAR-induced AMPK activation promotes
phosphorylation of IRS-1 at Ser794
Recently, we reported that treatment of ALL cell lines with
AICAR induced growth inhibition and apoptosis, and
resulted in increased expression of P-Akt (Ser473) [3].
Phosphorylation of Akt, especially at the Ser473 residue,
has been shown to be regulated by the mTOR/TORC2
complex [7,10-12], whereas phosphorylation of Akt at
Thr308 was shown to be regulated by mTOR but through
a feedback loop inhibition mechanism targeting IRS-1
[15-17]. To investigate the role of AMPK and mTOR in
this process, we examined the levels of P-mTOR (Ser2448)
and P-IRS-1 (Ser794, a residue known to be phosphory-
lated by AMPK) [31] in CCRF-CEM (T-ALL) and
NALM6 (Bp-ALL) cells treated with AICAR. As expected,
levels of P-AMPK and P-Akt (Ser473) were increased fol-
lowing treatment with AICAR (200 and 500 μM), while
expression of P-mTOR (Ser2448) was significantly
decreased (p < 0.001, for control vs. AICAR treated cells)
(Fig. 1). Concomitantly, expression of P-IRS-1 (Ser794)
was significantly increased in a dose dependent manner
(p < 0.05, for control vs. AICAR treated cells). These
changes in phosphorylated protein expression directly
correlated with level of P-AMPK (Thr172), and inversely
correlated with the degree of P-mTOR down-regulation
(Fig. 1). These data indicate that the compensatory
increase in P-Akt expression seen in AICAR-treated ALL
cells results from both activation of IRS-1 by AMPK, and
inhibition of the mTOR mediated feedback loop inhibition
of IRS-1 activity. Nevertheless, as previously demonstrated,
this compensatory up-regulation of P-Akt was unable to
rescue ALL cells from apoptotic death following AICAR-
induced AMPK activation [3].
AICAR-induced phosphorylation of Akt at Ser473 is
independent of IGF-1R/IRS-1 signaling in ALL but requires
AMPK activation
To characterize the extent to which the increase in P-
Akt expression was dependent on IGF-1R/IRS-1, we
used the specific tyrosine kinase inhibitor HNMPA(AM)
3 (IGF1Ri) to inhibit IGF-1R/IRS-1 signaling, and exam-
ined its effects on P-IRS-1 (Ser794) and P-Akt (Ser473
and Thr308) expression in AICAR-treated CCRF-CEM
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and NALM6 cells using Western immunoblotting. As
shown in Fig. 2, treatment with AICAR (200 μM) alone
for 24 h increased the expression of P-IRS-1 (Ser794)
and P-Akt at Ser473 and Thr308 by over two fold,
whereas treatment with HNMPA(AM)3 alone (IGF1Ri,
10 μM) decreased significantly the phosphorylation of
P-IRS-1 (Ser794) and P-Akt (Thr308) (p < 0.0001, for P-
IRS-1 expression in control vs. HNMPA(AM)3 treated
cells; p < 0.001, for P-Akt expression in control vs.
HNMPA(AM)3 treated cells), but had a negligible effect
on P-Akt (Ser473). More important, co-treatment with
an IGF-1R inhibitor in cells exposed to AICAR failed to
restore the observed AICAR-induced up-regulation of
P-IRS-1 (Ser794), and P-Akt (Thr308), while phosphory-
lation of Akt at Ser473 remained unaffected (Fig. 2, A +
IGF1Ri). These findings indicate that AICAR-induced
Akt phosphorylation at Thr308 is dependent of IGF-1R/
IRS-1 activation whereas phosphorylation of Akt at
Ser473 occurs independently of IGF-1R/IRS-1 signaling
but requires AMPK activation. Therefore, AMPK
Figure 1 Activation of AMPK induces phosphorylation of IRS-1 at Ser794 and down-regulation of mTOR (Ser2448) in ALL cell lines.
Western blot analysis of the expression of AMPK (Thr172), Akt (Ser473), mTOR (Ser2448) and IRS-1 (Ser794) in CCRF-CEM (T-ALL) and NALM6 (Bp-
ALL) cells treated with AICAR (200 and 500 μM) and incubated for 24 h at 37°C. The density value of each band was normalized to b-actin level
and expressed relative to control (shown as fold induction).
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activation by AICAR promotes activation of Akt by two
mechanisms: phosphorylation of Akt (Thr308) by IGF-
1R/IRS-1 (Ser794) signaling mediated by AMPK and its
downstream down-regulation of mTOR, and the other
through phosphorylation of Akt (Ser473) by an AMPK-
dependent mechanism.
To further investigate the role of AMPK in the activa-
tion of Akt, we compared the effects of the AMPK acti-
vator AICAR and compound-C, a known specific
inhibitor of AMPK [32,33]. Western blot analysis of pro-
tein extracts from CCRF-CEM and NALM6 cells treated
with either AICAR (100 & 200 μM) or compound-C
(2.5 & 5.0 μM) showed that activation of AMPK corre-
lated with phosphorylation of Akt at both residues
(Ser473 and Thr308), and conversely inhibition of
AMPK by compound-C also led to down-regulation P-
Akt at both residues (Fig. 3). To ascertain the affects of
P-AMPK in these experiments, the functional activation
or inhibition of AMPK signaling were confirmed by the
determining the phosphorylation status of P-ACC
(Ser79). As seen in Fig. 3, expression of P-ACC directly
correlated with the phosphorylation status of AMPK at
Thr172. These data together with data presented in Fig.
2, strongly suggest that functional AMPK signaling is
required for activation of Akt at both Ser473 and
Thr308, but the phosphorylation of Akt at Thr308 also
requires IGF-1R/IRS-1 signaling. Therefore, the com-
pensatory activation of Akt seen in ALL cells following
AICAR-induced AMPK activation resulted from phos-
phorylation of Akt at Thr308 and Ser473 (Fig. 2).
Inhibition of IGF-1R tyrosine kinase activity with HNMPA
(AM)3 induces growth inhibition and apoptosis in ALL cell
lines
Phosphorylation of Akt at Thr308 was shown to be suf-
ficient to induce Akt’s pro-survival effects [34] but phos-
phorylation of both residues is needed for optimal
activity. To examine the role of IGF-1R/IRS-1 signaling
in ALL cell survival, we evaluated the effects of IGF-1R
inhibition using HNMPA(AM)3 (2 - 100 μM) on cell
Figure 2 AICAR-induced AMPK activation phosphorylates Akt at Ser473 in a mechanism independent of IGF-1R/IRS-1 signaling in ALL
cell lines. Western blot analysis of P-IRS-1 (Ser794), P-Akt (Ser473), and P-Akt (Thr308) in CCRF-CEM and NALM6 cells treated with 0.1% DMSO
(CTRL), AICAR (200 μM), the IGF-1R tyrosine kinase inhibitor HNMPA(AM)3 (IGF1Ri, 10 μM), or both agents (A + IGF1Ri) and incubated for 24 h at
37°C. The levels of P-IRS-1 and P-Akt were normalized to b-actin (loading control) and expressed relative to control (shown as fold induction).
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growth and apoptosis using a panel of ALL cell models.
As shown in Fig. 4A, treatment of CCRF-CEM and
NALM6 cells with HNMPA(AM)3 inhibited their
growth in a dose-dependent manner with calculated
EC50 values of 16.5 μM and 6.1 μM for CCRF-CEM
and NALM6, respectively. We then extended our analy-
sis to other Bp-ALL subtypes characterized by the non-
random translocations REH [t(12;21)] and SupB15 [t
(9;22)]. In NALM6 treatment with HNMPA(AM)3 (10
μM) led to 50% growth inhibition compared to 40% and
25% in REH and SupB15 cells, respectively (Fig. 4B).
To determine if IGF-1R inhibition was cytostatic or
cytotoxic in ALL cells, we determined induction of
apoptosis in these same cell models. CCRF-CEM and
NALM6 cells were treated with increasing concentra-
tions of HNMPA(AM)3 (2 - 100 μM) and apoptosis was
assayed using Annexin V-FITC/PI staining. Fig. 4C
shows that HNMPA(AM)3 induced apoptotic cell death
in a dose-dependent manner in NALM6, and to a lower
extent in CCRF-CEM cells. Comparatively, the maximal
fold increase in apoptotic cell death was approximately
40-fold compared to control in NALM6 cells, whereas
only a 10-fold increase in apoptotic death was observed
in CCRF-CEM cells (Fig. 4C). Level of apoptosis in the
Bp-ALL subtypes REH [t(12;21)] and SupB15 [t(9;22)]
following treatment with HNMPA(AM)3 (10 μM) was
significantly lower compared to NALM6 cells (p =
0.0032, for NALM6 vs. REH; p = 0.0016, for NALM6 vs.
SupB15). REH and SupB15 cells exhibited only a 2-fold
increase in apoptotic cell death compared to a 6-fold
increase in NALM6 cells (Fig. 4D). Similar fold differ-
ences were observed over a range of drug concentra-
tions. Interestingly, the translocation t(9;22) encoding
for the BCR-ABL fusion protein expressed in SupB15
Figure 3 Functional AMPK activity is required for activation of Akt at Ser473 and Thr308 in ALL cell lines. CCRF-CEM and NALM6 cells
were exposed to either the AMPK activator AICAR (100 and 200 μM) or the AMPK inhibitor compound-C (CompC, 2.5 and 5.0 μM) for 24 h at
37°C. Proteins were extracted and analyzed by Western immunoblotting for the expression of P-Akt (Ser473 and Thr308), P-AMPK (Thr172), and
P-ACC (Ser79). The density value of each band was normalized to b-actin level and expressed relative to control (shown as fold induction).
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cells was shown to induce autocrine IGF-1 signaling in
leukemia, which may confer clinical resistance due to
higher IGF-1R signaling and constitutive P-Akt activity.
Taken together, these data raise the intriguing possibility
that cell lineage of origin (B- vs. T-ALL) and the pre-
sence of non-random translocations may modulate IGF-
1R activity and consequently may influence ALL cell
death vs. cell survival when exposed to IGF-1R
inhibitors.
Differential expression level of IGF-1R and downstream
signaling factors in ALL cells
The different levels of sensitivity to the IGF-1R inhibitor
observed among CCRF-CEM (T-ALL) and NALM6 (Bp-
ALL) cells, and within Bp-ALL REH and SupB15 sub-
types expressing selected non-random translocations
prompted us to investigate the mechanism underlying
these differences. To address this question, we per-
formed Western blot analysis of key factors associated
with the IGF-1R signaling cascade in these cell models.
As shown in Fig. 5A, NALM6 cells expressed higher
levels of phospho-IGF-1R (Tyr1131) and phospho-IRS-1
(Ser794) than CCRF-CEM cells. Similarly, lower levels
of expression of P-IGF-1R (Tyr1131) and P-IRS-1
(Ser794) were detected in the Bp-ALL REH [t(12;21)]
and SupB15 [t(9;22)] subtypes characterized by non-ran-
dom translocations in comparison to NALM6 (Fig. 5B).
In addition, the expression of P-Akt was higher in
CCRF-CEM cells (shown in Fig. 3) and REH cells (Fig.
5B), which correlated with these cell models having
either a mutation or a deletion in the PTEN gene,
respectively [35,36]. Similarly, the high level of P-Akt
found in SupB15 cells (carrying the BCR-ABL gene
fusion) results from inhibition of PP1a, a serine phos-
phatase that negatively regulates the PI3K/Akt pathway
[37]. Mechanistically, higher levels of IGF-1R/IRS-1
expression correlated with higher sensitivity to IGF-1R
inhibition, with NALM6 cells exhibiting the highest
expression of IGF-1R and the highest sensitivity to
apoptotic cell death following IGF-1R inhibition. As
expected, treatment with the IGF-1R inhibitor HNMPA
(AM)3 (IGF1Ri, 10 μM) reduced considerably the
expression of both IGF-1R and IRS-1 phosphorylated
proteins (Fig. 5A). Additionally, phosphorylation of IRS-
1 at Ser312, the residue targeted by mTOR and respon-
sible for the negative feedback-loop inhibition, was
inversely expressed compared to the expression of P-
IGF-1R (Tyr1131) in all the cells examined (Fig. 5A and
5B). The activity of P-mTOR was monitored using P-
4EBP1 (Thr70) expression, its immediate downstream
Figure 4 Inhibition of IGF-1R tyrosine kinase activity induces growth inhibition and apoptosis in ALL cell lines. Cell growth (A) and level
of apoptosis (C) detected in ALL CCRF-CEM and NALM6 cells treated with the IGF-1R inhibitor HNMPA(AM)3 (2 - 100 μM) and incubated for 24 h
at 37°C. Proliferation (B) and level of apoptosis (D) detected in Bp-ALL subtypes NALM6, REH (t[12;21]), and SupB15 (t[9;22]) treated with HNMPA
(AM)3 (10 μM) and incubated for 24 h at 37°C. The cell growth (viability) values are expressed as a percentage relative to those obtained with
untreated control cells (mean ± SEM, n = 3). Annexin V-FITC/PI staining data (apoptosis) were normalized and expressed as fold induction
relative to control values (mean ± SEM, n = 3) as described in Methods.
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target [38], and demonstrated that mTOR activity was
down-regulated in all cell lines following IGF-1R inhibi-
tion. These data further suggest that “addiction” of the
cells to IGF-1R activity as determined by P-IGF-1R
(Tyr1131) and P-IRS-1 (Ser312) expression makes cells
more dependent on IGF-1R signaling for survival, and
therefore more susceptible to IGF-1R inhibition.
Simultaneous inhibition of IGF-1R or Akt signaling
pathways with AMPK activator induces synergistic
cytotoxicity in ALL cell lines
Our laboratory and others have demonstrated that sig-
nificant functional cross-talk between AMPK, mTOR,
IGF-1R/IRS-1, and Akt signaling factors occur in leuke-
mia cells [3,9,39-42]. Since inhibition of IGF-1R activity
is capable of inducing growth inhibition and apoptotic
cell death, we reasoned that co-targeting these intercon-
nected pathways would result in enhanced cytotoxicity.
To test this hypothesis we tested three combination
strategies in ALL cell line models. First, we evaluated
agents targeting simultaneously the AMPK (AICAR, 100
μM) and IGF-1R (HNMPA(AM)3, 1 μM) signaling pro-
teins. This combination resulted in significant growth
inhibition (p < 0.001, for AICAR + HNMPA(AM)3 vs.
control, AICAR alone, and HNMPA(AM)3 alone) in
CCRF-CEM and NALM6 cell lines examined (Fig. 6A)
with a calculated combination index (CI) of 0.47 and
0.55 for CCRF-CEM and NALM6, respectively. Second,
we tested whether inhibition of Akt, downstream to
IGF-1R signaling, in the presence of AICAR would also
increase growth inhibition. As shown in Fig. 6B, combi-
nation of AICAR (200 μM) plus the Akt inhibitor X
(AIX, 9 μM) had similar effects with CI values of 0.90
and 0.85 for CCRF-CEM (p < 0.001, for AICAR + AIX
vs. control, AICAR alone, and AIX alone) and NALM6
(p < 0.05, for AICAR + AIX vs. control, AICAR alone,
and AIX alone), respectively. These results suggest that
blocking activation of Akt by either inhibiting IGF-1R/
IRS-1 activity or the downstream interference with Akt
phosphorylation, greatly increases the growth inhibition
when AMPK is simultaneously activated by AICAR in
ALL cells. Third, we tested the combined inhibition of
Figure 5 Expression level of IGF-1R and downstream regulated signaling factors in B-ALL vs. T-ALL cell lines. A) Western blot analysis of
P-IGF-1R (Tyr1131), P-IRS-1 (Ser794 and Ser312), and P-4EBP1 (Thr70) expression in Bp-ALL (NALM6) and T-ALL cells (CCRF-CEM) treated with 0.1%
DMSO (Control) or the IGF-1R inhibitor HNMPA(AM)3 (IGF1Ri, 10 μM) and incubated for 24 h. B) Basal expression level of P-IGF-1R (Tyr1131), P-
IRS-1 (Ser312), P-Akt (Thr308), and P-4EBP1 (Thr70) in Bp-ALL NALM6 and subtypes characterized by non-random translocations (REH (t[12;21]),
and SupB15 (t[9;22])). The levels of P-4EBP1 were normalized to b-actin (loading control) and expressed relative to control (shown as fold
induction).
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IGF-1R and mTOR, which is negatively regulated fol-
lowing AMPK activation [3]. For these experiments we
treated cells with the mTOR inhibitor rapamycin plus
the IGF-1R inhibitor HNMPA(AM)3. Although blocking
mTOR activity would have a negative effect on cell pro-
liferation secondary to inhibition of protein synthesis, it
would also relieve the feedback loop inhibition on IRS-1
activating Akt, which might promote cell growth. As
presented in Fig. 6C, treatment of CCRF-CEM and
NALM6 cells with rapamycin (1 μg/ml) and HNMPA
(AM)3 (0.5 - 1.0 μM) induced growth inhibition with CI
values of 0.41 and 0.88 for CCRF-CEM and NALM6
cells, respectively. Therefore, the three combination stra-
tegies tested resulted in synergistic growth inhibition in
both cell lines examined, as evidenced by CI values <1
in all cases.
We then analyzed induction of the cell death resulting
from these drug combinations and found that only the
combination AICAR plus AIX, targeting AMPK and Akt
simultaneously, was synergistic with a CI value of 0.89
and 0.78 for CCRF-CEM and NALM6 cell lines, respec-
tively (Fig. 7B). Although additional cell death was
observed for the other combinations as compared to
single drug alone, none of the cytotoxic effects resulting
Figure 6 Simultaneous inhibition of IGF-1R with drug altering AMPK, mTOR, or Akt signaling pathway induces synergistic growth
inhibition in ALL cell lines. Cell growth of ALL CCRF-CEM and NALM6 cells treated with either AICAR (100 μM) plus the IGF-1R inhibitor
HNMPA(AM)3 (1.0 μM) (panel A); AICAR (200 μM) plus the Akt inhibitor-X (AIX, 9.0 μM) (panel B); or rapamycin (1.0 μg/ml) plus HNMPA(AM)3 (0.5
and 1.0 μM) (panel C). Cells were treated with either agent alone or in combination at the indicated doses and incubated for 24 h at 37°C. The
cell growth values are expressed as a percentage relative to those obtained with control cells (mean ± SEM, n = 3). Combination index (CI)
values were determined for each drug combination as described in Methods (CI <1 indicates synergism).
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from the two other drug combinations were synergistic
(Fig. 7A and 7B). The combination HNMPA(AM)3 plus
AICAR resulted in a “borderline” CI of 0.99 and was
considered additive, whereas the combination of
HNMPA(AM)3 plus rapamycin was found to be antago-
nistic with CI >1. In both cases in which combination
therapy was either additive or synergistic in inducing
cell death in NALM6 and CCRF-CEM cells, activation
of AMPK signaling was co-targeted. These data suggest
that the master energy regulator AMPK plays a pivotal
role in triggering apoptotic cell death when these signal-
ing cascades are co-targeted, and that the cross-talk
between AMPK and the IGF-1R, Akt and mTOR
pathways appears to be important in determining cellu-
lar fate following perturbations of these cascades. Taken
together, our data indicate that blocking simultaneously
both the key cell proliferation regulator mTOR, and the
IGF-1R-induced Akt phosphorylation pathway resulted
in significant cell growth inhibition and cell death by
interfering with the mechanism of cell survival triggered
by treatment with single agents.
Discussion
In search for novel treatment strategies, we investigated
AMPK signaling as potential target for ALL therapy.
Our results, together with our previously published
Figure 7 Co-targeting AMPK and Akt signaling pathway induces synergistic cell death in ALL cell lines. Cell death values obtained from
the ALL CCRF-CEM and NALM6 cells shown in Fig. 6 which were treated with either AICAR (100 μM) plus the IGF-1R inhibitor HNMPA(AM)3 (1.0
μM) (panel A); AICAR (200 μM) plus the Akt inhibitor-X (AIX, 9.0 μM) (panel B); or rapamycin (1.0 μg/ml) plus HNMPA(AM)3 (0.5 and 1.0 μM)
(panel C). The cell death values were generated from the trypan blue exclusion data and are expressed as a percentage relative to those
obtained with control cells (mean ± SEM, n = 3). Combination index (CI) values were determined for each drug combination as described in
Methods (C <1, = 1, and >1 indicate synergism, additive effect, and antagonism, respectively).
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report [3] reveal that activation of AMPK by AICAR
induces a compensatory survival response through acti-
vation of Akt at both of its functional residues Ser473
and Thr308. Although phosphorylation of Akt at both
residues is critical for maximum catalytic activity [9,43],
it has been established that phosphorylation of Thr308
is sufficient to activate its kinase activity and support
cell survival [34]. We show that the mechanism of Akt
activation in ALL cells is mediated in part by AMPK-
induced phosphorylation of IRS-1 at Ser794, the
immediate downstream effectors of the IGF-1R signaling
cascade, and also in part by AMPK-induced inhibition
of mTOR and its downstream feedback loop inhibition
of IRS-1 (Ser312). Direct interaction between P-AMPK
(Thr172) and phosphorylation of IRS-1 at Ser794 has
been shown to occur in several systems such as cell
lines [31,44,45], and insulin-resistant animal models
[46], but the biological relevance of this phosphorylation
event is still not clear. Different functions have been
reported for AMPK-induced IGF-1R phosphorylation
with some reporting a positive effect on PI3K/Akt sig-
naling [31] whereas others reported a negative effect
[45-47]. Additive activation of AMPK and Akt has been
shown to regulate important biological functions such
as angiogenesis and glucose metabolism [48,49], suggest-
ing that positive interactions exist between AMPK and
Akt as we report here. Other reports demonstrated that
Akt could negatively regulate AMPK activity by direct
binding and phosphorylation of AMPK at Ser485
[50-52]. These opposite effects reflect the complexity of
the signaling cross-talk that exists between AMPK, IRS-
1, and downstream activation of Akt.
It is clear from our studies that phosphorylation of Akt
at Thr308 in AICAR-treated ALL cells occurs via direct
AMPK down-regulation of mTOR and activation of the
IGF-1R/IRS-1 signaling cascade. This compensatory
mechanism promotes cell survival because inhibition of
IGF-1R activity in either presence or absence of AICAR
decreases P-IRS-1 (Ser794) and P-Akt (Thr308) levels and
significantly increases apoptotic cell death. The signaling
cascade triggered by activation of tyrosine kinase receptor
leading to phosphorylation of IRS-1 and subsequent acti-
vation Akt at Thr308 have been extensively studied and is
mediated by the downstream PI3K and PDK1 kinases
[16,34,53]. Additionally, we demonstrate that phosphoryla-
tion of Akt is also dependent on AMPK since inhibition of
AMPK activity with compound-C clearly decreased P-Akt
at both residues. AMPK has been shown to inhibit
mTORC1 activity by two different mechanisms: one
through activation of the TSC2, which promotes down-
stream inhibition of the mTOR activator Rheb [9,54], and
the other through direct phosphorylation of Raptor at
Ser792 blocking mTORC1 activation [55]. Additional stu-
dies demonstrated that phosphorylation of Akt at Ser473
was mediated by mTORC2, a complex formed by the
association of rictor, mSin1, mLST8, with mTOR
[7,10,12,34,56,57]. Among mTORC1 and mTORC2,
mTOR is the only critical factor that is shared by both
complexes [9]. Thus, it is tempting to speculate that by
down-regulating mTORC1, AMPK could increase the
availability of mTOR and favor the formation of
mTORC2, which would promote phosphorylation of Akt
at Ser473. A similar mechanism was proposed for activa-
tion of Akt by AMPK in macrophages expressing a consti-
tutively active form of AMPK [58]. Nevertheless, we can
not rule out the possibility that a distinct mechanism inde-
pendent of mTORC2 might be involved in this process.
The data presented herein shows that activity of IGF-
1R/IRS-1 was higher in NALM6 vs. CCRF-CEM cells,
and that their expression also differs within Bp-ALL
REH and SupB15 subtypes characterized by the non-
random translocations t[12;21], and t[9;22]. More
important, these differences correlated with reduction in
P-IRS-1 (Ser794) and P-Akt (Ser473 and Thr308), and
degree of induction of apoptotic death resulting from
the pharmacological inhibition of IGF-1R. Our results
raise the intriguing possibility that cell lineage of origin
and/or presence of selected non-random translocations
may influence response to therapy in ALL cells treated
with inhibitors of IGF-1R. This possibility needs to be
investigated using primary samples from patients with
ALL. It is also possible that the level of Akt activation
in these cells may also dictate their degree of sensitivity
to IGF-1R inhibition. For instance, it is well known that
the CCRF-CEM cell line carries a mutation inactivating
PTEN [35] and that REH cells born a PTEN deletion
[36], both leading to increased reliance on Akt signaling
for cell survival. In addition, SupB15 cells express high
levels of P-Akt because the expression of the BCR-ABL
gene fusion inhibits PP1a, a serine phosphatase that
negatively regulates the PI3K/Akt pathway [37]. Interest-
ingly, the expression level of P-Akt was the lowest in
NALM6 cells which was also the most sensitive to the
IGF-1R inhibitor HNMPA(AM)3 as compared to all of
the other cell lines examined, therefore suggesting that
Akt provides a mechanism to escape cell death following
IGF-1R inhibition.
To further assess whether IGF-1R signaling may be
influenced by biological pathways closely linked to cell
lineage and non-random chromosomal translocations,
we have mined existing gene expression databases from
childhood ALL patients http://www.stjuderesearch.org/
data/ALL1, and found that the expression of relevant
IGF-1 regulatory carriers such as IGFBP2 and IGFBP4
appear to be significantly differentially expressed in ALL
in a phenotype specific manner. The known correlation
between these carriers and IGF-1 suggested to us that
differences in IGF-1 signaling may exist in ALL, and
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impact critical oncogenic and survival signaling path-
ways. Interestingly, IGF-1R signaling has been linked to
cell lineage of origin in ALL. For instance, significant
differences in the expression of the IGF-1 system com-
ponents IGF-II, IGFBP-2, IGFBP-4 and IGFBP-5 have
been described between B-lineage and T-lineage ALL
[28-30]. IGFBP-2 was identified as the major regulatory
carrier in childhood leukemia and exhibited an inverse
correlation with IGF-1 levels [59], suggesting that activa-
tion of IGF-1R signaling may confer ALL cells a survival
advantage and influence induction of apoptosis. Emer-
ging literature suggests that IGF-1R signaling may also
be influenced by non-random translocations in ALL
[60,61]. For instance, leukemia cells expressing the
translocation t(9;22) encoding for the BCR-ABL fusion
not only exhibit a higher degree of resistance to che-
motherapeutic drugs but also were shown to induce
autocrine IGF-1 signaling. Thus, it is clear that IGF-1R
pathway may provide ALL cells a survival advantage
through its crosstalk with other critical metabolic
networks.
The identification of potential cross-talk within com-
pensatory survival pathways in ALL cells prompted us
to developed simultaneous co-targeting strategies to
induce cell death in ALL cells. We demonstrated that
co-targeting IGF-1R and downstream pathways (AMPK
& IGF-1R, mTOR & IGF-1R, and AMPK & Akt) led to
synergistic growth inhibition in ALL cell models. This is
consistent with the study of Bertrand et al. [62] that
demonstrated that blocking IGF-1R activity using an
antibody synergized with inhibitors of PI3K/Akt/mTOR
pathway by suppressing the IGF-1R-induced Akt phos-
phorylation, and consequently promoted apoptosis in
hematopoietic cells. Among the three drug combina-
tions tested, only the one co-targeting AMPK and Akt
resulted in synergistic induction of cell death. This can
be explained in part by differences in the mechanism of
action between AIX vs. HNMPA(AM)3, with AIX being
more effective in inactivating Akt. Taken together,
rationally designed simultaneous targeting of key factors
within the AMPK, IGF-1R, and mTOR pathways leads
to synergistic induction of cell growth inhibition by
blocking compensatory survival responses triggered by
treatment with single agents. Nevertheless, of the com-
binations strategies tested only co-targeting AMPK plus
Akt lead to synergistic induction of apoptosis.
Conclusions
We conclude that IGF-1R and its downstream metabolic
and oncogenic pathways contribute to cell survival and
are important to determine pro- or anti-apoptotic
responses in ALL cells to treatment with inhibitors of
these signaling pathways. Our data suggest that PTEN
status, AMPK and Akt signaling, and possibly cell-
lineage and non-random translocations, influence IGF-
1R signaling and sensitivity to IGF-1R inhibitors in ALL
lymphoblasts. Selected combination strategies aimed at
inhibiting IGF-1R and related downstream pathways
represent a potential strategy for future translation into
novel ALL therapies, in particular when AMPK is one
of the signaling proteins targeted in these combinations.
Methods
Cell lines and chemicals
The childhood ALL cell lines CCRF-CEM (T-lineage),
NALM6 (Bp-lineage), REH (Bp-ALL/t(12;21)) were grown
in RPMI 1640 medium supplemented with 10% FBS and
antibiotics. SupB15 (Bp-ALL/t(9;22)) were grown in
Iscove’s modified DMEM medium with 20% FBS. Cell cul-
ture media were purchased from Cellgro (Mediatech, Inc,
Manassas, VA). All other cell culture reagents were from
Invitrogen Corporation (Carlsbad, CA). Cells were treated
with agents known to activate AMPK (AICAR, Toronto
Research Chemicals, Inc, Ontario, Canada)) or inhibit
IGF-1R (HNMPA(AM)3), mTOR (rapamycin, LC Labora-
tories, Woburn, MA), or Akt (Akt inhibitor-X, EMD
Chemicals, Inc., Gibbstown, NJ), and incubated for periods
of 24 to 48 h (5% CO2 at 37°C).
Cell proliferation assays
Cell viability (500 μl) was determined using the Vi Cell XR
system (Beckman-Coulter), and values are expressed as a
percentage relative to those obtained in untreated controls
(means ± SEM, n = 3). Synergism was determined using
the Chou’s combination index (CI) based on the following
equation: CI = [(D1 combination/D1 single) + (D2 combination/D2
single)] [63]. The numerators D1 combination and D2 combina-
tion represent the concentration of the drug D1 and D2,
respectively, used in the combination treatment that inhi-
bits cell growth by x%. The denominators D1 single and D2
single represent the concentration of drug D1 and D2 as
single agent needed to achieve the same level of growth
inhibition than in the combination (x%).
Apoptosis assays
Apoptosis was evaluated using the Annexin V-FITC
Apoptosis Detection Kit I following the manufacturer’s
recommendations (BD Biosciences, San Jose, CA). Briefly,
cells were washed twice with 1× PBS pH 7.4, resuspended
to [1 × 106 cells/ml] in 1× Binding Buffer, then 100 μl of
cells were incubated with a mixture of Annexin V/Propi-
dium Iodide (PI) reagents for 15 min/RT°C, equilibrated
with 400 μl 1× Binding Buffer, and fluorescence was ana-
lyzed by flow cytometry (BD Biosciences LSR II flow
cytometer; University of Miami-SCCC Flow Cytometry
Core Facility). Apoptotic Annexin V/PI staining values
were combined, and normalized to control values (fold
induction).
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Western immunoblotting
Protein extracts were prepared by sonication in the pre-
sence of protease inhibitors, and quantified using the
Micro BCA Protein Assay Kit (Pierce, Rockford, IL).
Proteins (50 μg/lane) were resolved by 4-15% SDS-
PAGE (Bio-Rad, Hercules, CA), transferred onto PVDF
membranes (Invitrogen, Carlsbad, CA) and immunode-
tected using a Western Lighting ECL system (Perkin
Elmer, Waltham, MA). For immunodetection of P-
AMPK (Thr172), P-Akt (Ser473 & Thr308), P-IRS-1
(Ser312 & Ser794), P-IGF-1R (Tyr1131), P-4EBP1
(Thr70), P-mTOR (Ser2448), and b-actin, we used speci-
fic primary antibody against each protein and horserad-
ish peroxidase-conjugated secondary antibody (anti IgG)
(Cell Signaling, Danvers, MA). Expression of each pro-
tein was determined by densitometry analysis of the
immunodetected bands, normalized to b-actin, and
expressed relative to control (fold induction). The
immunoblots shown are representative of 3 independent
experiments, which produced similar results.
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